Imunon Historical Financial Ratios
| IMNN Stock | USD 0.86 0.03 3.61% |
Imunon is lately reporting on over 90 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as PTB Ratio of 0.48 or Days Sales Outstanding of 86.81 will help investors to properly organize and evaluate Imunon Inc financial condition quickly.
Imunon |
About Imunon Financial Ratios Analysis
Imunon IncFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Imunon investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Imunon financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Imunon history.
Imunon Financial Ratios Chart
Add Fundamental
Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Book Value Per Share
The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.Most ratios from Imunon's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Imunon Inc current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Imunon Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, Imunon's PTB Ratio is very stable compared to the past year. As of the 27th of November 2024, Capex To Depreciation is likely to grow to 0.66, while Price To Sales Ratio is likely to drop 21.07.
| 2023 | 2024 (projected) | Days Sales Outstanding | 91.37 | 86.81 | PTB Ratio | 0.46 | 0.48 |
Imunon fundamentals Correlations
Click cells to compare fundamentals
Imunon Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Imunon fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 74.67 | 45.38 | 93.48 | 19.29 | 22.18 | 21.07 | |
| Ptb Ratio | 2.56 | 1.22 | 0.84 | 0.33 | 0.46 | 0.48 | |
| Days Sales Outstanding | 39.74 | 49.87 | 15.6 | 79.46 | 91.37 | 86.81 | |
| Book Value Per Share | 10.0 | 8.73 | 9.67 | 4.11 | 1.48 | 1.41 | |
| Free Cash Flow Yield | (0.55) | (0.69) | (0.35) | (2.43) | (3.17) | (3.01) | |
| Operating Cash Flow Per Share | (13.92) | (7.33) | (2.81) | (3.24) | (2.1) | (2.21) | |
| Average Payables | 3.1M | 3.2M | 2.9M | 3.6M | 3.2M | 1.9M | |
| Stock Based Compensation To Revenue | 4.6 | 3.8 | 7.6 | 5.4 | 4.86 | 3.21 | |
| Capex To Depreciation | 0.48 | 0.0257 | 0.44 | 0.37 | 0.63 | 0.66 | |
| Pb Ratio | 2.56 | 1.22 | 0.84 | 0.33 | 0.46 | 0.48 | |
| Ev To Sales | 83.59 | 23.45 | 67.58 | 8.83 | 10.16 | 9.65 | |
| Free Cash Flow Per Share | (14.16) | (7.34) | (2.87) | (3.28) | (2.15) | (2.26) | |
| Net Income Per Share | (11.58) | (10.08) | (3.6) | (5.03) | (2.16) | (2.27) | |
| Payables Turnover | 3.66 | 4.56 | 5.05 | 0.28 | 0.2 | 0.19 | |
| Sales General And Administrative To Revenue | 16.0 | 15.28 | 21.78 | 27.38 | 31.48 | 29.91 | |
| Research And Ddevelopement To Revenue | 26.13 | 22.69 | 21.24 | 23.47 | 26.99 | 25.64 | |
| Capex To Revenue | 0.28 | 0.7 | 0.0382 | 0.62 | 0.54 | 0.59 | |
| Cash Per Share | 10.21 | 8.06 | 8.58 | 4.6 | 1.74 | 1.65 | |
| Pocfratio | (3.52) | (1.84) | (1.45) | (2.88) | (0.32) | (0.34) | |
| Interest Coverage | (14.76) | (14.3) | (37.71) | (5.45) | (6.27) | (6.58) | |
| Capex To Operating Cash Flow | (0.0172) | (0.001222) | (0.0192) | (0.0116) | (0.0237) | (0.0249) | |
| Pfcf Ratio | (1.81) | (1.45) | (2.83) | (0.41) | (0.32) | (0.33) | |
| Days Payables Outstanding | 79.98 | 72.22 | 1.3K | 1.8K | 1.8K | 1.1K | |
| Income Quality | 1.2 | 0.73 | 0.78 | 0.64 | 0.97 | 0.58 | |
| Roe | (1.16) | (1.15) | (0.37) | (1.22) | (1.46) | (1.53) | |
| Ev To Operating Cash Flow | (2.06) | (0.75) | (2.08) | (0.19) | (0.1) | (0.11) | |
| Pe Ratio | (2.22) | (1.06) | (2.25) | (0.27) | (0.32) | (0.33) | |
| Ev To Free Cash Flow | (2.03) | (0.75) | (2.04) | (0.19) | (0.0995) | (0.1) | |
| Intangibles To Total Assets | 0.47 | 0.41 | 0.18 | (0.1) | (0.0921) | (0.0875) | |
| Net Debt To E B I T D A | 0.19 | (0.27) | 0.52 | 0.62 | 0.16 | 0.21 | |
| Current Ratio | 2.06 | 2.79 | 7.67 | 3.7 | 2.47 | 2.34 | |
| Tangible Book Value Per Share | 2.2 | (2.4) | 1.48 | 7.35 | 4.74 | 1.41 | |
| Receivables Turnover | 9.18 | 7.32 | 23.4 | 4.59 | 4.13 | 3.93 | |
| Graham Number | 51.05 | 44.51 | 27.98 | 21.55 | 8.48 | 8.05 |
Pair Trading with Imunon
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Imunon position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Imunon will appreciate offsetting losses from the drop in the long position's value.Moving together with Imunon Stock
| 0.72 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.86 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.9 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
Moving against Imunon Stock
| 0.87 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.85 | NAMS | NewAmsterdam Pharma | PairCorr |
| 0.54 | PMVP | Pmv Pharmaceuticals | PairCorr |
| 0.4 | PHVS | Pharvaris BV | PairCorr |
| 0.35 | ESLAW | Estrella Immunopharma | PairCorr |
The ability to find closely correlated positions to Imunon could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Imunon when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Imunon - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Imunon Inc to buy it.
The correlation of Imunon is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Imunon moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Imunon Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Imunon can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Imunon Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Imunon. If investors know Imunon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Imunon listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.91) | Revenue Per Share 0.014 | Return On Assets (0.67) | Return On Equity (1.48) |
The market value of Imunon Inc is measured differently than its book value, which is the value of Imunon that is recorded on the company's balance sheet. Investors also form their own opinion of Imunon's value that differs from its market value or its book value, called intrinsic value, which is Imunon's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Imunon's market value can be influenced by many factors that don't directly affect Imunon's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Imunon's value and its price as these two are different measures arrived at by different means. Investors typically determine if Imunon is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Imunon's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.